CLINICAL RESEARCH: COST EFFECTIVENESS AND REGULATORY CONSIDERATIONS
Cost Effectiveness of Cardiac Resynchronization Therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial
Arthur M. Feldman, MD, PhD, FACC*,*,
Gregory de Lissovoy, PhD , ,
Michael R. Bristow, MD, PhD, FACC ,
Leslie A. Saxon, MD, FACC||,
Teresa De Marco, MD, FACC¶,
David A. Kass, MD, FACC,
John Boehmer, MD, FACC#,**,
Steven Singh, MD, FACC,,
David J. Whellan, MD*,
Peter Carson, MD, FACC,,
Audra Boscoe, MPH,
Timothy M. Baker, BS and
Matthew R. Gunderman, MBA
* Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania
MEDTAP Institute at UBC, Bethesda, Maryland
Department of Health Policy Management, Johns Hopkins School of Public Health, Baltimore, Maryland
Division of Cardiology, University of Colorado, Denver, Colorado
|| Division of Cardiology, University of Southern California, Los Angeles, California
¶ Division of Cardiology, University of California, San Francisco, California
# Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
** Division of Cardiology, Hershey Medical Center, Hershey, Pennsylvania
Department of Medicine and Pharmacology at Georgetown University School of Medicine, Washington, DC
Veterans Affairs Medical Center, Washington, DC
Guidant Corporation, St. Paul, Minnesota
Manuscript received February 25, 2005;
revised manuscript received July 7, 2005,
accepted August 9, 2005.
* Reprint requests and correspondence: Dr. Arthur M. Feldman, Department of Medicine, Jefferson Medical College, 1025 Walnut Street, Philadelphia, Pennsylvania 19107 (Email: arthur.feldman{at}jefferson.edu).
A preliminary report of this work was presented at the 54th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, 2005.
OBJECTIVES: The analysis goal was to estimate incremental cost-effectiveness ratios (ICERs) for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial patients who received cardiac resynchronization therapy (CRT) via pacemaker (CRT-P) or pacemaker-defibrillator (CRT-D) in combination with optimal pharmacological therapy (OPT) relative to patients with OPT alone.
BACKGROUND: In the COMPANION trial, CRT-P and CRT-D reduced the combined risk of all-cause mortality or first hospitalization among patients with advanced heart failure and intraventricular conduction delays, but the cost effectiveness of the therapy remains unknown.
METHODS: In this analysis, intent-to-treat trial data were modeled to estimate the cost effectiveness of CRT-D and CRT-P relative to OPT over a base-case seven-year treatment episode. Exponential survival curves were derived from trial data and adjusted by quality-of-life trial results to yield quality-adjusted life-years (QALYs). For the first two years, follow-up hospitalizations were based on trial data. The model assumed equalized hospitalization rates beyond two years. Initial implantation and follow-up hospitalization costs were estimated using Medicare data.
RESULTS: Over two years, follow-up hospitalization costs were reduced by 29% for CRT-D and 37% for CRT-P. Extending the cost-effectiveness analysis to a seven-year base-case time period, the ICER for CRT-P was $19,600 per QALY and the ICER for CRT-D was $43,000 per QALY relative to OPT.
CONCLUSIONS: For the COMPANION trial patients, the use of CRT-P and CRT-D was associated with a cost-effectiveness ratio below generally accepted benchmarks for therapeutic interventions of $50,000 per QALY to $100,000 per QALY. This suggests that the clinical benefits of CRT-P and CRT-D can be achieved at a reasonable cost.
|
Abbreviations and Acronyms
| | COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial | | CRT = cardiac resynchronization therapy | | CRT-D = cardiac resynchronization therapy with pacemaker-defibrillator | | CRT-P = cardiac resynchronization therapy with pacemaker | | DRG = diagnostic-related group | | ICER = incremental cost-effectiveness ratio | | LV = left ventricular | | MLHFQ = Minnesota Living With Heart Failure Questionnaire | | NYHA = New York Heart Association | | OPT = optimal pharmacological therapy | | QALY = quality-adjusted life-year |
|
This article has been cited by other articles:
|
|
|
|
 
G. Boriani, M. Biffi, C. Martignani, I. Diemberger, C. Valzania, M. Bertini, and A. Branzi
Expenditure and value for money: the challenge of implantable cardioverter defibrillators
QJM,
May 1, 2009;
102(5):
349 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The CRT Survey Scientific Committee
European cardiac resynchronization therapy survey: rationale and design
Eur J Heart Fail,
March 1, 2009;
11(3):
326 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Cohen and M. R. Reynolds
Interpreting the results of cost-effectiveness studies.
J. Am. Coll. Cardiol.,
December 16, 2008;
52(25):
2119 - 2126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Swedberg, J. Cleland, M. R. Cowie, M. Nieminen, S. G. Priori, L. Tavazzi, D. J. van Veldhuisen, L. Alonso-Pulpon, J. Camm, K. Dickstein, et al.
Successful treatment of heart failure with devices requires collaboration
Eur J Heart Fail,
December 1, 2008;
10(12):
1229 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Blomstrom, M. Ekman, C. B. Lundqvist, M.J. Calvert, N. Freemantle, S. Lonnerholm, G. Wikstrom, and B; Jonsson
Cost effectiveness of cardiac resynchronization therapy in the Nordic region: An analysis based on the CARE-HF trial
Eur J Heart Fail,
September 1, 2008;
10(9):
869 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace,
September 1, 2008;
10(9):
1034 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K H Lam and A. Owen
Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials
BMJ,
November 3, 2007;
335(7626):
925 - 925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Europace,
October 1, 2007;
9(10):
959 - 998.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Eur. Heart J.,
September 2, 2007;
28(18):
2256 - 2295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. McAlister, J. Ezekowitz, N. Hooton, B. Vandermeer, C. Spooner, D. M. Dryden, R. L. Page, M. A. Hlatky, and B. H. Rowe
Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction: A Systematic Review
JAMA,
June 13, 2007;
297(22):
2502 - 2514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al.
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail,
June 1, 2007;
9(6-7):
684 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hlatky and D. B. Mark
The high cost of implantable defibrillators
Eur. Heart J.,
February 2, 2007;
28(4):
388 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Yao, N. Freemantle, M. J. Calvert, S. Bryan, J.-C. Daubert, and J. G.F. Cleland
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
Eur. Heart J.,
January 1, 2007;
28(1):
42 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Kramer
The Expanding Prognostic Role of Late Gadolinium Enhanced Cardiac Magnetic Resonance
J. Am. Coll. Cardiol.,
November 21, 2006;
48(10):
1986 - 1987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Krumholz and F. A. Masoudi
The Year in Epidemiology, Health Services Research, and Outcomes Research
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1886 - 1895.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ward, S. Guo, and J. J. Caro
Cost-Effectiveness of Cardiac Resynchronization Therapy
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1283 - 1283.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kearney, G. Stokoe, G. Breithardt, C. Longson, J. Marco, J. Morgan, S. Priori, A. Ruether, R. Taylor, M. Hertog, et al.
Improving patient access to novel medical technologies in Europe
Eur. Heart J.,
April 1, 2006;
27(7):
882 - 885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O.-A. Breithardt and G. Breithardt
Quest for the Best Candidate: How Much Imaging Do We Need Before Prescribing Cardiac Resynchronization Therapy?
Circulation,
February 21, 2006;
113(7):
926 - 928.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hlatky
Cost Effectiveness of Cardiac Resynchronization Therapy
J. Am. Coll. Cardiol.,
December 20, 2005;
46(12):
2322 - 2324.
[Full Text]
[PDF]
|
|
|
|
